(Q53363647)

13 May 2018

title

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. (English)

1 reference

13 May 2018

main subject

phase I clinical trial

0 references

0 references

1 reference

David I Bernstein

1

1 reference

13 May 2018

Elizabeth A Reap

2

1 reference

13 May 2018

Kevin Katen

3

1 reference

13 May 2018

Aubrey Watson

4

1 reference

13 May 2018

Kaitlin Smith

5

1 reference

13 May 2018

Pamela Norberg

6

1 reference

13 May 2018

Robert A Olmsted

7

1 reference

13 May 2018

Amy Hoeper

8

1 reference

13 May 2018

John Morris

9

1 reference

13 May 2018

Sarah Negri

10

1 reference

13 May 2018

Maureen F Maughan

11

1 reference

13 May 2018

Jeffrey D Chulay

12

1 reference

13 May 2018

language of work or name

English

0 references

publication date

24 October 2009

1 reference

13 May 2018

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

13 May 2018

volume

28

1 reference

13 May 2018

page(s)

484-493

1 reference

13 May 2018

issue

2

1 reference

13 May 2018

Atherosclerosis and infection due to Chlamydia pneumoniae or cytomegalovirus: weighing the evidence

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Cytomegalovirus infection: a driving force in human T cell immunosenescence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Autoimmune response to U1 small nuclear ribonucleoprotein (U1 snRNP) associated with cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Congenital cytomegalovirus infection: epidemiology and treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Cytomegalovirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

The outcome of congenital cytomegalovirus infection in relation to maternal antibody status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Therapeutic and prophylactic applications of alphavirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Development and preclinical evaluation of an alphavirus replicon vaccine for influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Alphavirus vectors and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Vaccine prevention of maternal cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

T-cell quality in memory and protection: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

inferred from DOI database lookup

7 January 2021

based on heuristic

DNA immunization confers protection against murine cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.135

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.09.135

1 reference

13 May 2018

PubMed ID

19857446

1 reference

13 May 2018